Key Takeaways
- Quality: free cash flow of $17.7B exceeds implied net income of about $10.3B, but the payout ratio is 117.3% and the current ratio is 0.87.
- Growth: revenue grew 10.3% (TTM) against a 5-year CAGR of 1.8%, while the 2282.1% earnings growth figure likely reflects a depressed base.
- Opportunity: the stock is at its two-year high of $295.03 with a P/E of 50.69 and a 3.4% free cash flow yield, leaving a thin valuation cushion.
This AbbVie Inc. stock analysis opens with a stock at its peak: at $295.03, AbbVie shares are trading right at their two-year high. The business behind the price is highly profitable and generates plenty of cash, yet the valuation has risen and the dividend is paying out more than the company reports in earnings.
What Is Happening With the Stock Price
AbbVie (ABBV) trades at $295.03, equal to its two-year high and up from a two-year low of $164.99. The stock sits at the upper end of its range, so recent buyers have been rewarded, and the market cap stands at $521.50B. Trading at a peak can reflect improving sentiment, but it also means the shares have less room for disappointment than they did earlier in the window.
Earnings per share are $5.82 and the P/E ratio is 50.69, a high multiple for a large pharmaceutical company with modest long-run growth.
Quality: Is This a Financially Sound Business?
Profitability is solid. Gross margin is 73.7%, operating margin is 36.6% and net profit margin is 15.7%. Return on assets is 10.7%. Return on equity and debt-to-equity are N/A, so leverage cannot be judged on those measures.
The cash flow check is favorable. Revenue (TTM) is $66.0B, so a 15.7% net margin implies net income of roughly $10.3B, while free cash flow (TTM) is $17.7B. Cash generation therefore exceeds reported profit, which suggests earnings are well supported, though non-cash charges such as amortization may explain part of the gap. Liquidity is thinner: the current ratio is 0.87 and the quick ratio is 0.56, both below 1. This AbbVie Inc. stock analysis therefore treats the balance sheet as a watch item. The model’s Quality score is 73/100.
The dividend yield is 2.4%, but the payout ratio is 117.3%, meaning dividends exceed reported earnings. Free cash flow covers the payout more comfortably than earnings do, but the ratio leaves less flexibility if profits dip.
Growth: Does This Company Have Real Upside?
Revenue growth (TTM) is 10.3%, well above the 5-year CAGR of 1.8%, so growth has recently accelerated from a slow long-run pace. Earnings growth (TTM) is 2282.1%, a figure that almost certainly reflects a depressed prior-year base, for example from one-time charges, rather than a repeatable rate. It should not be extrapolated.
EV/Revenue is 8.97 and EV/EBITDA is 18.59. With a Growth score of 56/100, the model sees decent but not exceptional momentum, helped by the high gross margin.
Opportunity: Is Now a Good Time to Enter?
Valuation is the limiting factor. The P/E of 50.69 is elevated and the free cash flow yield is 3.4%. Price-to-book is N/A. With the stock at its two-year high, there is no pullback to improve the entry point, and the Opportunity score is 35/100.
The bull case is a recovering top line, strong margins and cash flow ahead of earnings. The bear case is that a stock at a two-year peak with a stretched multiple, weak liquidity ratios and a payout above 100% could be vulnerable if growth slows or earnings disappoint.
AbbVie Inc. Stock Analysis: The Bottom Line
The AbbVie Inc. stock analysis ends with a Hold signal from the StreetBriefs scoring model: Quality 73/100, Growth 56/100, Opportunity 35/100, and a Recommendation score of 55/100. The business quality is real, but the valuation and the stock’s position at its high keep the signal short of a Buy.
Risks include the 117.3% payout ratio, the current ratio of 0.87, and the 2282.1% earnings growth figure, which flatters trend readings. The Hold label reflects the model’s quantitative scoring and is a starting point for further research, not a personalized recommendation to transact.
Financial Metrics Summary
| Metric | Value |
|---|---|
| Price & Valuation | |
| Current Price | $295.03 |
| 2-Year Low | $164.99 |
| 2-Year High | $295.03 |
| Market Cap | $521.50B |
| P/E Ratio | 50.69 |
| EV / Revenue | 8.97 |
| Our Scores | |
| Quality Score | 73 / 100 |
| Growth Score | 56 / 100 |
| Opportunity Score | 35 / 100 |
| Profitability | |
| Earnings Per Share | $5.82 |
| Return on Assets | 10.7% |
| Net Profit Margin | 15.7% |
| Gross Margin | 73.7% |
| Operating Margin | 36.6% |
| Growth | |
| Revenue Growth (5Y CAGR) | 1.8% |
| Revenue Growth (TTM) | 10.3% |
| Earnings Growth (TTM) | 2282.1% |
| Balance Sheet | |
| Current Ratio | 0.87 |
| Quick Ratio | 0.56 |
| Income & Dividends | |
| Dividend Yield | 2.4% |
| Payout Ratio | 117.3% |
Data as of November 16, 2026
Our Three-Pillar Assessment
| Quality |
73/100 |
| Growth |
56/100 |
| Opportunity |
35/100 |
Quality measures business fundamentals: profitability, cash flow discipline, and balance sheet strength.
Growth captures revenue momentum, gross margin scalability, and the Rule of 40 efficiency test.
Opportunity signals entry timing: current valuation versus history and price position in the 2-year range.
Current price: $295.03 trading 0% above its 2-year high of $295.03.
Keep researching ABBV
Follow ABBV’s scores in Qubits Finance
The Quality, Growth and Opportunity scores above come from the same model that powers the Qubits Finance screener. Compare ABBV with its peers, keep it on a watchlist, and see when its scores change. There, the model’s Buy, Hold and Sell signals read Positive, Neutral and Caution.
See ABBV in the screener →What Qubits Finance offers
The screener is on the free plan; accounts are approved by a person during the private beta. Research tools and information only: Qubits Finance does not place trades or make personal recommendations. Want a stock we have not covered? Request an analysis.
This analysis is done using financial data from Yahoo Finance.
Always conduct your own due diligence and consult a qualified financial advisor before making investment decisions.